Brian Wehrle is the Vice President of Research and Development for Medical Imaging at Clario, where he spearheads efforts to push the boundaries of medical imaging technology. With over 25 years of dedicated experience in medical imaging, Brian is passionate about delivering innovative solutions that exceed client expectations. Under his leadership, Clario has seen the successful buildup of its Medical Imaging AI team, significantly enhancing its capabilities in this critical area. Additionally, Brian played a pivotal role in driving the creation of a Generative AI team, further solidifying Clario’s position at the forefront of AI in healthcare. His commitment to innovation and excellence in medical imaging makes him a respected leader and a visionary in the field.
Archives: Speakers
Shalome Sine
Shalome Sine is a Senior Manager and Quantitative Insights Specialist at the Center for Information and Study on Clinical Research Participation (CISCRP).
Shalome believes that the patient’s voice can be a powerful force toward building inclusive, efficient clinical trials. Through her work, she hopes to help clinical trial sponsors and teams bring actionable patient insights into practice to improve clinical trial operational processes.
Shalome manages both quantitative and qualitative patient voice projects, specializing in quantitative, survey-based patient insights projects. She holds a Master of Public Health from Tufts University and a Bachelor of Science from Penn State University.
Urania Rappo
Dr Rappo is Senior Director of clinical development at BiomX, a biotech company developing phage cocktails designed to target and destroy harmful bacteria. Prior to joining BiomX in 2020, Dr Rappo worked on the clinical development of dalbavancin and other anti-infectives at Durata Therapeutics, Actavis and Allergan. As an adult infectious disease physician, she focuses on developing safer and more effective treatment options for difficult to treat infections.
Ashley Sullivan
Ashley Sullivan has more than 13 years’ experience in clinical research. As Director of Study Start-up at Allucent, Ashley is responsible for leading, developing and coordinating activities and staff within Study Start-up & Site Intelligence and developing and implementing business strategies to ensure quality and timely performance of all start-up activities. She guided the overhaul and implementation of a specialized SSU module within CTMS allowing for improved metric tracking and reporting. Ashley also focuses on collaborating across functional areas to ensure a smooth working relationship between Study Start-up and other departments for overall successful trial conduct and delivery for clients.
Krishna Allamneni
With over two decades of pharmaceutical industry experience, I excel in strategically navigating benefit-risk profiles for diverse therapeutic modalities, from monoclonal antibodies to small molecules, and for various therapeutic areas including Oncology, Hematology, CNS, Infectious, Autoimmune, Diabetes, Liver & Metabolism, to name a few. My leadership style prioritizes people, fostering trust and collaboration at all levels. I am a forward-thinking leader in R&D strategy and tactical planning, and a highly regarded operational manager for key R&D functions. My Biopharma R&D expertise includes early development leadership of about 25 IND/IMPD programs, 7 NDA/MAA approvals, and a track record of efficiently developing therapeutic candidates. I have had impactful global regulatory interactions with FDA, MHRA, BfArM, ANSM, PMDA, Health Canada, TGA etc. during clinical development, partnership, and commercialization. Currently, I’m the Chief Development Officer at Concarlo Therapeutics, Inc., driving early-stage “pipeline in a target” towards clinical development. Previously, at Turning Point Therapeutics, Inc., I led a lean, outsourced DevSci function, contributing to a $2B+ valuation and a $200M follow-on offering. In addition, my background spans leadership roles at Jazz Pharmaceuticals, Inc., NGM Biopharmaceuticals, Inc., Genentech, Celera Genomics and other industry leaders. My education includes a Ph.D. in Pharmacology/Toxicology and certification from the American Board of Toxicology. I volunteer for California Life Sciences as their Scientific Advisor on FAST Kansai program. I am a member of the WIB Board Room Ready 2023 cohort. As a dedicated member of professional organizations like the American College of Toxicology and Society of Toxicology, I actively contribute to advancing the field. I thrive in fast-paced environments, leveraging a strategic mindset and a biotech approach to achieve results.
